In 2023, a Delphi committee was convened to update the nomenclature of nonalcoholic fatty liver disease. The rationale for this change was because of the recognition that "nonalcoholic" did not accurately capture the etiology (cause) of the disease. In addition, "fatty" was viewed as stigmatizing by some. A new nomenclature was developed to recognize steatotic liver disease (SLD) as a spectrum of conditions based on the identification of significant alcohol use and/or metabolic risk factors. [1]

In response, the Fatty Liver Foundation made several updates to the survey including:

• updating the survey name to "The State of Steatotic (Fatty) Liver Care in America" 
• expanding eligibility to any individual diagnosed with a condition under the SLD umbrella term and not just MASLD or MASH
• adding a question to specify SLD sub-classification diagnosis
• where relevant, updating question answer choices to be more inclusive of the expanded eligible population

Sign up to be included in next year's survey!

Click the images below for an in-depth review of our findings from 2024 and previous years.

Wayne Eskridge (FLF CEO & Co-Founder) and Neeraj Mistry (FLF Chief Medical Officer) discuss findings at the AASLD's The Liver Meeting 2024.

References

1. Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., & Kanwal, F. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology. Advance online publication. Doi:10.1016/j.jhep.2023.01.022.